GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
C3572 JD5037Summary: inverse agonist at CB1 receptors -
C3573 4-Quinolone-3-Carboxamide CB2 LigandSummary: ligand of the CB2 receptor -
C3828 1-(1-Naphthyl) piperazine (hydrochloride)Summary: ligand for 5-HT receptors -
C3886 BW A868CSummary: prostaglandin D2 antagonist -
C3909 R-Palmitoyl-(1-methyl) EthanolamideSummary: synthetic analog of palmitoyl ethanolamide (PEA) -
C3924 2-fluoro Palmitic AcidSummary: inhibits sphingosine biosynthesis and long-chain acyl-CoA synthetase -
C3965 Rilmenidine (hemifumarate)Summary: I1-imidazoline binding site selective ligand and α2-adrenoceptor agonist -
C3990 Lofexidine (hydrochloride)Summary: α2-adrenergic receptor agonist -
C3901 ONO-8711Summary: EP1 receptor antagonist -
C3786 Guanabenz (hydrochloride)Summary: α2-adrenergic receptor agonist

